RXRX - CIK 0001601830
RECURSION PHARMACEUTICALS, INC. (RXRX) reported revenue of $74.68M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $74.68M | +26.9% |
| FY 2024 | $58.84M | +32.0% |
| FY 2023 | $44.58M | +11.9% |
| FY 2022 | $39.84M | +291.5% |
| FY 2021 | $10.18M | +156.9% |
| FY 2020 | $3.96M | +70.8% |
| FY 2019 | $2.32M | - |
RECURSION PHARMACEUTICALS, INC. (RXRX) reported revenue of $74.68M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2019 and fiscal 2025, RECURSION PHARMACEUTICALS, INC.'s revenue grew from $2.32M to $74.68M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.